A Phase 3 interventional study of Entecavir (ETV) and Adefovir (ADV) in Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 61 sites in 17 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.
Among the 37 studies testing entecavir in Hepatitis B, this one is the 9th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2003, is one of 4 in phase 3, and was the 2nd registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:
Bangladesh Medical University · Sites in Bangladesh
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 20
First in 2001; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 195 is above the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 106 across the 36 interventional studies. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Hepatitis B by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Hepatitis B by Bristol-Myers Squibb, this one is one of 3 that started in 2003, is one of 2 in phase 3, and was the 2nd registered.
Bristol-Myers Squibb’s Hepatitis B studies by the year they started, since 2001.
3 of the studies testing entecavir in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05453435Sun Yat-sen UniversityEntecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) | 2026-12 |
| NCT07816094Bangladesh Medical UniversityComparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver | 2027-01-19 |
| NCT07189377University Health Network, TorontoCombined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies testing entecavir in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 12 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir (ETV)
Drug: Adefovir (ADV)
Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
Also known as: Baraclude, BMS-200475
Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24
Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis.
Time frame: Baseline, Week 24
Change From Baseline in HBV DNA by PCR at Week 48
Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status.
Time frame: Baseline, Week 48
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24
Time frame: Week 24
Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48
Time frame: Week 48
Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48
Number of participants in each group who achieved ALT normalization (≤1.0 x upper limit of normal \[ULN\]) among those with baseline ALT \>1.0 x ULN at Weeks 24 and 48
Time frame: Week 24, Week 48
Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48
Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48
Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
Change From Baseline in Child-Pugh Score Through Week 48
Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48
Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C.
Time frame: Week 24, Week 48
Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48
Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Improvement or No Worsening in MELD Score Through Week 48
Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
Mean Changes From Baseline in Quality of Life as Measured by the Short Form 36 (SF-36)
Scoring for the SF-36 will be done using the algorithm developed by the Research ANd Development(RAND) Corporation (a scale of 0-100). Higher scores represent better quality of life. Coding for items with 2-category responses=0 and 100; 3-category=0/50/100; 5-category=0/25/50/75/100; 6-category=0/20/40/60/80/100. Scores of items in the same scale are combined to create the 8 scale scores (physical functioning, role-physical, bodily-pain, general health, vitality, social functioning, role-emotional, mental health). Physical and mental health composite scores will be computed for the group.
Time frame: Baseline, Week 24, Week 48
Mean Changes From Baseline in Quality of Life, as Measured by EuroQol-5D (EQ-5D) at Weeks 24 and 48
The EQ-5D has 5 attributes (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression), each with 3 levels (no problem, some problems, and major problems). This algorithm gives valuation (weights) to each of the 15 responses on the form. Each valuation is a negative number, subtracted from the maximum score of 1 (perfect well being). The overall health index score ranges from 0 (dead) to 1 (perfect health) value scale, and the visual analog scale ranges from 0 to 100. Item weights will be obtained from the EuroQol group.
Time frame: Baseline, Week 24, Week 48
Change From Baseline in Albumin Through Week 48
Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Mean Change From Baseline in Prothrombin Time Through Week 48
Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Mean Change From Baseline in Total Bilirubin Through Week 48
Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Change From Baseline in Platelet Count Through Week 48
Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10\*9 c/L.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Participants Achieving Albumin Normalization Through Week 48
Number of participants who achieved normalization of albumin (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Participants Achieving Prothrombin Time Normalization Through Week 48
Number of participants who achieved normalization of prothrombin time (\<= 1 x ULN), a measure of liver function, at specific timepoints.
Time frame: Baseline, Week4, Week 8, Week 12, Week 24, Week 36, Week 48
Participants Achieving Total Bilirubin Normalization Through Week 48
Number of participants who achieved normalization of total bilirubin (\<= 1 x ULN), a measure of liver function, at specific timepoints.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Participants Achieving Platelet Count Normalization Through Week 48
Number of participants who achieved normalization of platelet count (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48
Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48
HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points.
Time frame: Week 48
Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL
AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values ≥0.5 mg/dL compared with baseline on 2 sequential measures.
Time frame: on-treatment events obtained after the start of therapy and no more than 5 days after the last dose of study therapy.
Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data
Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.
Time frame: Week 48=all on-treatment laboratory measurements up to Week 48. Cumulative data = on-treatment laboratory measurements obtained after the start of therapy and no more than 5 days after the last dose of study therapy.
Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment
ALT flare=ALT \> 2 x baseline and \> 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio \> 1.5 or prothrombin time \>= 1.2 x ULN and total bilirubin \>2.5 mg/dL and \> 1 mg/dL increase from baseline.
Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date.
Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period
Data includes type of malignant neoplasm.
Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.
Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up
Time frame: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.
| Milestone | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Started | 100 | 91 |
| Treated (as-randomized population) | 100 | 91 |
| Treated (as-treated population) | 102 | 89 |
| Treated, wk 48 (as-treated population) | 102 | 89 |
| Treated, 24-week follow-up population | 25 | 28 |
| Completed | 71 | 62 |
| Not completed | 29 | 29 |
| Withdrew: Death | 16 | 17 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 6 |
| Withdrew: Poor/non-compliance | 3 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Subject withdrew consent | 2 | 1 |
| Withdrew: Subject no longer meets study criteria | 1 | 0 |
Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis.
| log10 copies/mL | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24 | -4.48 ± 0.200 | -3.40 ± 0.255 |
Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status.
| log10 copies/mL | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Change From Baseline in HBV DNA by PCR at Week 48 | -4.66 ± 0.204 | -3.90 ± 0.353 |
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24 | 49 | 15 |
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48 | 57 | 18 |
Number of participants in each group who achieved ALT normalization (≤1.0 x upper limit of normal \[ULN\]) among those with baseline ALT \>1.0 x ULN at Weeks 24 and 48
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Week 24 | 46 | 28 |
| Week 48 | 49 | 33 |
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 3 | 1 |
| Week 4 | 23 | 6 |
| Week 8 | 34 | 11 |
| Week 12 | 37 | 16 |
| Week 24 | 49 | 24 |
| Week 48 | 57 | 34 |
Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 14 | 11 |
| Week 8 | 23 | 10 |
| Week 12 | 22 | 11 |
| Week 24 | 32 | 22 |
| Week 36 | 35 | 19 |
| Week 48 | 35 | 25 |
Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 66 | 67 |
| Week 8 | 67 | 62 |
| Week 12 | 68 | 62 |
| Week 24 | 66 | 65 |
| Week 48 | 61 | 61 |
Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).
| units on a scale | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=100, n=91) | 8.8 ± 0.20 | 8.4 ± 0.19 |
| Change at Week 4 (n=90; n=85) | -0.4 ± 0.14 | -0.3 ± 0.14 |
| Change at Week 8 (n=90; n=79) | -0.4 ± 0.18 | -0.3 ± 0.17 |
| Change at Week 12 (n=87; n=80) | -0.6 ± 0.18 | -0.3 ± 0.15 |
| Change at Week 24 (n=80; n=77) | -1.2 ± 0.20 | -0.7 ± 0.18 |
| Change at Week 36 (n=75; n=70) | -1.6 ± 0.25 | -0.9 ± 0.18 |
| Change at Week 48 (n=72; n=64) | -1.7 ± 0.26 | -1.3 ± 0.19 |
Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C.
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Week 24 | 25 | 22 |
| Week 48 | 35 | 29 |
Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.
| units on a scale | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=100; n=91) | 17.1 ± 0.50 | 15.3 ± 0.48 |
| Week 4 (n=97; n=87) | -0.1 ± 0.38 | 0.1 ± 0.25 |
| Week 8 (n=90; n=79) | -0.8 ± 0.35 | -0.4 ± 0.34 |
| Week 12 (n=88; n=80) | -1.2 ± 0.41 | -0.9 ± 0.32 |
| Week 24 (n=80; n=77) | -2.0 ± 0.45 | -0.9 ± 0.46 |
| Week 36 (n=75; n=70) | -2.3 ± 0.57 | -1.2 ± 0.48 |
| Week 48 (n=72; n=62) | -2.6 ± 0.62 | -1.7 ± 0.50 |
Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; \<10=4% mortality.
| Participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 58 | 51 |
| Week 8 | 63 | 52 |
| Week 12 | 67 | 60 |
| Week 24 | 62 | 51 |
| Week 48 | 53 | 47 |
Scoring for the SF-36 will be done using the algorithm developed by the Research ANd Development(RAND) Corporation (a scale of 0-100). Higher scores represent better quality of life. Coding for items with 2-category responses=0 and 100; 3-category=0/50/100; 5-category=0/25/50/75/100; 6-category=0/20/40/60/80/100. Scores of items in the same scale are combined to create the 8 scale scores (physical functioning, role-physical, bodily-pain, general health, vitality, social functioning, role-emotional, mental health). Physical and mental health composite scores will be computed for the group.
No measurements were reported for this outcome.
The EQ-5D has 5 attributes (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression), each with 3 levels (no problem, some problems, and major problems). This algorithm gives valuation (weights) to each of the 15 responses on the form. Each valuation is a negative number, subtracted from the maximum score of 1 (perfect well being). The overall health index score ranges from 0 (dead) to 1 (perfect health) value scale, and the visual analog scale ranges from 0 to 100. Item weights will be obtained from the EuroQol group.
No measurements were reported for this outcome.
Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL.
| g/dL | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=100; n=91) | 3.00 ± 0.55 | 3.10 ± 0.067 |
| Change at Week 4 (n=98; n=88) | -0.04 ± 0.032 | -0.01 ± 0.033 |
| Change at Week 8 (n=92; n=82) | 0.01 ± 0.034 | -0.03 ± 0.037 |
| Change at Week 12 (n=88; n=80) | 0.05 ± 0.039 | 0.03 ± 0.037 |
| Change at Week 24 (n=81; n=77) | 0.26 ± 0.056 | 0.20 ± 0.048 |
| Change at Week 36 (n=76; n=70) | 0.36 ± 0.062 | 0.25 ± 0.052 |
| Change at Week 48 (n=72; n=63) | 0.49 ± 0.061 | 0.34 ± 0.057 |
Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds.
| seconds | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=100; n=91) | 16.28 ± 0.234 | 15.35 ± 0.196 |
| Change at Week 4 (n=98; n=87) | -0.08 ± 0.156 | 0.03 ± 0.114 |
| Change at Week 8 (n=91; n=79) | -0.10 ± 0.158 | 0.06 ± 0.161 |
| Change at Week 12 (n=88; n=80) | -0.29 ± 0.153 | -0.05 ± 0.162 |
| Change at Week 24 (n=80; n=77) | -0.75 ± 0.216 | -0.18 ± 0.205 |
| Change at Week 48 (n=72; n=63) | -0.99 ± 0.288 | -0.52 ± 0.197 |
Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL.
| mg/dL | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=100; n=91) | 2.80 ± 0.207 | 2.50 ± 0.214 |
| Change at Week 4 (n=98; n=88) | -0.06 ± 0.154 | 0.21 ± 0.172 |
| Change at Week 8 (n=92; n=82) | 0.11 ± 0.376 | -0.17 ± 0.094 |
| Change at Week 12 (n=88;l n=80) | -0.20 ± 0.193 | -0.28 ± 0.109 |
| Change at Week 24 (n=81; n=77) | -0.41 ± 0.154 | -0.14 ± 0.227 |
| Change at Week 36 (n=76; n=70) | -0.36 ± 0.329 | -0.09 ± 0.298 |
| Change at Week 48 (n=72; n=63) | -0.61 ± 0.233 | -0.10 ± 0.450 |
Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10\*9 c/L.
| 10*9 c/L | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline Value (n=97; n=91) | 87.32 ± 4.771 | 93.31 ± 4.947 |
| Change at Week 4 (n=90; n=85) | -0.93 ± 2.064 | -2.14 ± 2.553 |
| Change at Week 8 (n=82; n=76) | 3.55 ± 3.063 | 3.88 ± 2.923 |
| Change at Week 12 (n=85; n=79) | 4.36 ± 2.837 | -0.81 ± 2.814 |
| Change at Week 24 (n=77; n=76) | 2.47 ± 2.556 | -2.89 ± 3.205 |
| Change at Week 36 (n=72; n=69) | 6.56 ± 3.534 | 1.32 ± 3.188 |
| Change at Week 48 (n=68; n=63) | 10.19 ± 4.956 | 3.05 ± 3.570 |
Number of participants who achieved normalization of albumin (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 2 | 7 |
| Week 8 | 9 | 6 |
| Week 12 | 6 | 11 |
| Week 24 | 20 | 14 |
| Week 36 | 29 | 14 |
| Week 48 | 32 | 20 |
Number of participants who achieved normalization of prothrombin time (\<= 1 x ULN), a measure of liver function, at specific timepoints.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 3 | 4 |
| Week 8 | 5 | 4 |
| Week 12 | 4 | 3 |
| Week 24 | 9 | 6 |
| Week 36 | 10 | 5 |
| Week 48 | 8 | 7 |
Number of participants who achieved normalization of total bilirubin (\<= 1 x ULN), a measure of liver function, at specific timepoints.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 4 | 9 |
| Week 8 | 10 | 9 |
| Week 12 | 8 | 9 |
| Week 24 | 12 | 10 |
| Week 36 | 9 | 17 |
| Week 48 | 15 | 18 |
Number of participants who achieved normalization of platelet count (\>= 1 x lower limit of normal \[LLN\]), a measure of liver function, at specific timepoints.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Baseline | 0 | 0 |
| Week 4 | 3 | 4 |
| Week 8 | 3 | 5 |
| Week 12 | 7 | 3 |
| Week 24 | 2 | 2 |
| Week 36 | 5 | 2 |
| Week 48 | 6 | 1 |
HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points.
| HCC events | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Weeks 0-4 (n=102; n=89) | 2 | 3 |
| Weeks 4-8 (n=99; n=86) | 5 | 5 |
| Weeks 8-12 (n=96; n=83) | 10 | 6 |
| Weeks 12-16 (n=90; n=80) | 11 | 9 |
| Weeks 16-20 (n=87; n=77) | 11 | 11 |
| Weeks 20-24 (n=86; n=75) | 16 | 14 |
| Weeks 24-28 (n=81; n=71) | 17 | 15 |
| Weeks 28-32 (n=78; n=70) | 17 | 17 |
| Weeks 32-36 (n=77; n=66) | 17 | 18 |
| Weeks 36-40 (n=77; n=64) | 19 | 20 |
| Weeks 40-44 (n=73; n=62) | 21 | 20 |
| Weeks 44-48 (n=71; n=62) | 24 | 22 |
AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values ≥0.5 mg/dL compared with baseline on 2 sequential measures.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Any AE | 91 | 86 |
| Grade 3/4 AEs | 55 | 42 |
| SAEs | 70 | 59 |
| Deaths | 23 | 29 |
| HCC | 12 | 18 |
| Discontinuations due to AEs | 7 | 5 |
| Confirmed creatinine increase >= 0.5 mg/dL | 17 | 21 |
Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.
| participants | Week 48 - Entecavir (ETV) 1.0 mg | Week 48 - Adefovir (ADV) 10 mg | Cumulative - Entecavir (ETV) 1.0 mg | Cumulative - Adefovir (ADV) 10 mg |
|---|---|---|---|---|
| Hemoglobin | 8 | 8 | 11 | 10 |
| International Normalized Ratio | 30 | 22 | 40 | 32 |
| Platelet Count | 20 | 21 | 25 | 24 |
| Prothrombin Time | 20 | 7 | 25 | 11 |
| Bicarbonate, Low | 3 | 4 | 4 | 4 |
| Chloride, Serum, Low | 2 | 2 | 2 | 2 |
| Bicarbonate/Carbon Dioxide, Low | 3 | 4 | 4 | 4 |
| Potassium, Serum, High | 1 | 0 | 1 | 0 |
| Sodium, Serum | 6 | 3 | 6 | 5 |
| Sodium, Serum, Low | 6 | 3 | 6 | 5 |
| Lipase, Total (colorimetric assay) | 17 | 18 | 23 | 25 |
| Alanine Aminotransferase (ALT) | 3 | 1 | 5 | 4 |
| Albumin | 9 | 3 | 9 | 3 |
| Alkaline Phosphatase (ALP) | 0 | 1 | 1 | 1 |
| Aspartate Aminotransferase (AST) | 7 | 3 | 9 | 7 |
| Bilirubin, Total | 19 | 18 | 24 | 25 |
| G-Glutamyl Transferase (GGT) | 1 | 6 | 9 | 10 |
| Glucose, Fasting Serum, High | 0 | 0 | 1 | 0 |
| Creatinine | 1 | 0 | 2 | 0 |
| Phosphorus, inorganic | 0 | 4 | 0 | 6 |
| Blood, urine | 13 | 13 | 18 | 22 |
| Glucose, urine | 11 | 11 | 17 | 13 |
| Protein, urine | 1 | 2 | 2 | 4 |
| Neutrophils (relative) | 0 | 1 | 0 | 1 |
| Neutrophils + Bands (relative) | 2 | 4 | 4 | 8 |
| Neutrophils (absolute) | 2 | 3 | 5 | 7 |
ALT flare=ALT \> 2 x baseline and \> 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio \> 1.5 or prothrombin time \>= 1.2 x ULN and total bilirubin \>2.5 mg/dL and \> 1 mg/dL increase from baseline.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| ALT flares | 2 | 1 |
| ALT flares, no clinical events/lab abnormalities | 1 | 0 |
| ALT flares, with clinical events/lab abnormalities | 1 | 1 |
Data includes type of malignant neoplasm.
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Any Adverse Events | 14 | 18 |
| Hepatic Neoplasm, Malignant | 12 | 18 |
| Basal Cell Carcinoma | 1 | 0 |
| Lymph Node Cancer, Metastatic | 1 | 0 |
| Hepatic Mass | 1 | 0 |
| participants | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg |
|---|---|---|
| Liver Transplant: Yes | 11 | 3 |
| Liver Transplant: No | 91 | 86 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADEFOVIR | — | 59/89 (66.3%) | 76/89 (85.4%) |
| ENTECAVIR | — | 70/102 (68.6%) | 77/102 (75.5%) |
| Event | ADEFOVIR | ENTECAVIR |
|---|---|---|
| HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 15/89 | 12/102 |
| PROTHROMBIN TIME PROLONGEDInvestigations | 13/89 | 14/102 |
| HEPATIC ENCEPHALOPATHYNervous system disorders | 9/89 | 10/102 |
| HEPATIC FAILUREHepatobiliary disorders | 2/89 | 10/102 |
| BLOOD BILIRUBIN INCREASEDInvestigations | 6/89 | 8/102 |
| LIVER TRANSPLANTSurgical and medical procedures | 0/89 | 7/102 |
| PERITONITIS BACTERIALInfections and infestations | 6/89 | 6/102 |
| INTERNATIONAL NORMALISED RATIO INCREASEDInvestigations | 5/89 | 5/102 |
| SEPSISInfections and infestations | 3/89 | 5/102 |
| ASCITESGastrointestinal disorders | 4/89 | 4/102 |
| Event | ADEFOVIR | ENTECAVIR |
|---|---|---|
| OEDEMA PERIPHERALGeneral disorders | 21/89 | 18/102 |
| HEADACHENervous system disorders | 18/89 | 7/102 |
| DIARRHOEAGastrointestinal disorders | 18/89 | 15/102 |
| PYREXIAGeneral disorders | 16/89 | 20/102 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 14/89 | 19/102 |
| COUGHRespiratory, thoracic and mediastinal disorders | 15/89 | 17/102 |
| ASCITESGastrointestinal disorders | 14/89 | 14/102 |
| FATIGUEGeneral disorders | 13/89 | 13/102 |
| ABDOMINAL PAINGastrointestinal disorders | 12/89 | 14/102 |
| VOMITINGGastrointestinal disorders | 8/89 | 12/102 |
| Age Continuous(years) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Mean | 51 ± 12 | 53 ± 11 | 52 ± 11 |
| Sex: Female, Male(Participants) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Female | 22 | 27 | 49 |
| Male | 78 | 64 | 142 |
| Race/Ethnicity, Customized(participants) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Asian | 55 | 49 | 104 |
| White | 35 | 28 | 63 |
| Other | 5 | 9 | 14 |
| Black/African American | 5 | 5 | 10 |
| Region of Enrollment(participants) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| United States | 12 | 9 | 21 |
| Philippines | 4 | 5 | 9 |
| Taiwan | 11 | 11 | 22 |
| Hong Kong | 5 | 5 | 10 |
| Greece | 8 | 5 | 13 |
| Thailand | 10 | 9 | 19 |
| Indonesia | 2 | 0 | 2 |
| Turkey | 3 | 1 | 4 |
| Russian Federation | 1 | 1 | 2 |
| India | 15 | 14 | 29 |
| Canada | 5 | 3 | 8 |
| Brazil | 13 | 13 | 26 |
| Poland | 3 | 5 | 8 |
| Singapore | 3 | 5 | 8 |
| South Africa | 3 | 4 | 7 |
| France | 2 | 0 | 2 |
| United Kingdom | 0 | 1 | 1 |
| Child-Pugh Class(Participants) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Class A | 7 | 10 | 17 |
| Class B | 63 | 61 | 124 |
| Class C | 30 | 20 | 50 |
| Alanine Aminotransferase (ALT)(U/L) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Mean | 99.2 ± 111.23 | 100.0 ± 81.68 | 99.6 ± 98.01 |
| Child-Pugh Score(units on a scale) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Mean | 8.81 ± 1.98 | 8.35 ± 1.82 | 8.59 ± 1.91 |
| HBV DNA by PCR(log10 copies/mL) | Entecavir (ETV) 1.0 mg | Adefovir (ADV) 10 mg | Total |
|---|---|---|---|
| Mean | 7.53 ± 1.829 | 8.16 ± 2.179 | 7.83 ± 2.023 |
1 further baseline measures are reported on the registry.
The record gives a start of Aug 2003, a primary completion of Oct 2008 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir